VK5211 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hip Fractures
Conditions
Hip Fractures
Trial Timeline
Oct 30, 2015 → Dec 17, 2017
NCT ID
NCT02578095About VK5211 + Placebo
VK5211 + Placebo is a phase 2 stage product being developed by Viking Therapeutics for Hip Fractures. The current trial status is completed. This product is registered under clinical trial identifier NCT02578095. Target conditions include Hip Fractures.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02578095 | Phase 2 | Completed |
Competing Products
12 competing products in Hip Fractures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide + Placebo | Eli Lilly | Approved | 85 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| Zoledronic Acid 5Mg/Bag 100Ml Inj + sodium chloride | Roche | Approved | 85 |
| Denosumab 70 mg/mL + Zoledronic acid 4 mg + Placebo IV + Placebo SC | Amgen | Phase 3 | 76 |
| rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2/3 | 64 |
| rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| InductOs | Pfizer | Approved | 84 |
| rhBMP-2/CPM | Pfizer | Phase 1 | 32 |
| rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| Tranexamic Acid plus standard of care | Pfizer | Approved | 84 |
| CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536 | Pfizer | Phase 2 | 51 |
| enoxaparin (XRP4563) | Sanofi | Phase 3 | 76 |